JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 9, 2008; DOI: 10.1124/jpet.107.135046


0022-3565/08/3261-153-162$20.00
JPET 326:153-162, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.135046v1
326/1/153    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Dai, Y.
Right arrow Articles by Muma, N. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, Y.
Right arrow Articles by Muma, N. A.

NEUROPHARMACOLOGY

Transglutaminase-Catalyzed Transamidation: A Novel Mechanism for Rac1 Activation by 5-Hydroxytryptamine2A Receptor Stimulation

Y. Dai, N. L. Dudek, T. B. Patel, and N. A. Muma

Neuroscience Program, Loyola University Medical Center, Maywood, Illinois (Y.D.); Department of Pharmacology and Experimental Therapeutics, School of Medicine, Loyola University Chicago, Maywood, Illinois (N.L.D., T.B.P.); and Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, Kansas (N.A.M.)

Transglutaminase (TGase)-induced activation of small G proteins via 5-hydroxytryptamine (HT)2A receptor signaling leads to platelet aggregation (Cell 115:851–862, 2003). We hypothesize that stimulation of 5-HT2A receptors in neurons activates TGase, resulting in transamidation of serotonin to a small G protein, Rac1, thereby constitutively activating Rac1. Using immunoprecipitation and immunoblotting, we show that, in rat cortical cell line A1A1v, serotonin increases TGase-catalyzed transamidation of Rac1. This transamidation occurs in both undifferentiated and differentiated cells. Treatment with a 5-HT2A/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine, but not the 5-HT1A receptor agonist 5-hydroxy-2-dipropylamino tetralin, increases transamidation of Rac1 by TGase. In A1A1v cells, 5-HT2A receptors mediate the transamidation reaction because expression of 5-HT2C receptors was not detectable and the selective 5-HT2A receptor antagonist blocked transamidation. Time course studies demonstrate that transamidation of Rac1 is significantly elevated after 5 and 15 min of serotonin treatment, but returns it to control levels after 30 min. The activity of Rac1 is also transiently increased following serotonin stimulation. Inhibition of TGase by cystamine or small interfering RNA reduces TGase modification of Rac1, and cystamine also prevents Rac1 activation. Serotonin itself is bound to Rac1 by TGase following 5-HT2A receptor stimulation as demonstrated by coimmunoprecipitation experiments and a dose-dependent decrease of serotonin-associated Rac1 by cystamine. These data support the hypothesis that Rac1 activity is transiently increased due to TGase-catalyzed transamidation of serotonin to Rac1 via stimulation of 5-HT2A receptors. Activation of Rac1 via TGase is a novel effector and second messenger of the 5-HT2A receptor-signaling cascade in neurons.


Address correspondence to: Dr. Nancy A. Muma, Department of Pharmacology and Toxicology, 5064 Malott Hall, University of Kansas, 1251 Wescoe Hall Dr., Lawrence, KS 66045. E-mail: nmuma{at}ku.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.